Research Progress of TCM Treatment of Tumor-related Cardiovascular Toxicity
DOI:
https://doi.org/10.53469/jcmp.2024.06(11).08Keywords:
Traditional Chinese medicine, Cardiovascular toxicity, Antitumor therapy, Oncology cardiologyAbstract
Cancer is the second leading cause of death in the world. At present, cardiovascular disease has become the second leading cause of death for tumor survivors following tumor recurrence and metastasis. Early diagnosis and prevention of cardiovascular toxicity that may occur during the treatment of cancer patients. Cardiovascular toxicity related to cancer treatment includes cardiac insufficiency and heart failure (heart failure), coronary heart disease, immune myocarditis, hypertension, thromboembolic disease and other cardiovascular diseases. As a branch of the medical field, Chinese medicine is well known in the prevention and treatment of malignant tumors, and Chinese medicine therapy is a potential candidate for the treatment of tumor-related cardiotoxicity. This article summarizes the recent research progress of TCM therapy for anti-tumor cardiotoxicity related to tumor therapy.
References
Mao Guoping, Qin Yanru. Cardiovascular toxicity and long-term management strategies related to tumor therapy [J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2017, 9(01): 124-125+128.
Zhang XXIN, Zhang Yanli, Fang Fengqi, et al. Progress of prevention and treatment strategies for antitumor treatment-related cardiac dysfunction [J]. Chinese Journal of Cardiology, 2023, 28(06): 595-600.
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
DENT S, LIU P, BREZDEN-MASLEY C, et al. Cancer and Cardiovascular Disease: The Complex Labyrinth [J]. J Oncol, 2015, 2015: 516450.
LYON A R, LoPEZ-FERNaNDEZ T, COUCH L S, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [J]. European heart journal, 2022, 43(41): 4229-4361.
Sun Tao. Update of cardiotoxicity in chemotherapy and immunotherapy in 2023 CSCO Guidelines for Cancer Cardiology [J]. Journal of Practical Oncology, 2023, 38(5): 434-439.
Chinese Society of Clinical Oncology, Chinese Society of Hematology, Harbin Institute of Hematologic Tumors. Chinese expert Consensus on Prevention and Treatment of cardiotoxicity of anticancer drugs (2011 edition) [J]. Journal of Clinical Oncology, 2011, 16(12): 1122-1129.
Liu J, Luo L, Yu T, et al. Traditional Chinese Medicine understanding and treatment of chemotherapy-induced cardiotoxicity [J]. Shandong Journal of Traditional Chinese Medicine, 2020, 39(12): 1291-1294.
Fu Qiang, Li Zhong, Wu Hongjin. Study on TCM diagnosis and treatment of cardiotoxicity related to tumor treatment based on Jueyin theory [J]. Journal of Cardio-Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, 2024, 22(05): 942-944.
Chang Fuye, Wang Yongyan, Zhang Yunling, et al. On Toxicology in Traditional Chinese Medicine [J]. Global Chinese Medicine, 2009, 2(02): 115-117.
Li Yanyang, Sun Haiyan, Jiang Shengli, et al. Study on prevention and treatment of cardiotoxicity of antitumor drugs by traditional Chinese medicine [J]. Chinese Journal of Basic Medicine of Traditional Chinese Medicine, 2018, 24(11): 1602-1606.
Zhang GUoxia, Su Xin, Shang Hongcai, et al. Explore the pathogenesis of tumor heart disease in TCM from "poison damage heart collateral" [J]. Journal of Traditional Chinese Medicine, 2022, 63(14): 1394-1396.
SUTER T M, EWER M S. Cancer drugs and the heart: importance and management [J]. Eur Heart J, 2013, 34(15): 1102-1111.
Liu Xiaohong, Shang Ru Ru. Research progress of cardiac dysfunction related to cancer treatment [J]. Chin J Med, 2019, 54(08): 832-836. (in Chinese)
Chen Guangwen, Zhao Lin. Prevention and treatment of antineoplastic drug-related cardiac dysfunction [J]. Journal of Chinese Academy of Medical Sciences, 2019, 41(06): 842-850. (in Chinese)
Wang W, Li Z, Li K. Yiqi Yangxin Decoction prevents cardiotoxicity of anthracyclines in adjuvant chemotherapy for breast cancer [J]. Chinese Journal of Traditional Chinese Medicine, 2015, 33(10): 2535-2537.
Zhang Y, Zhao Haibin. Qishenyiqi dropping pills for treating antitumor drug-related cardiac dysfunction: a clinical observation. Beijing Traditional Chinese Medicine, 2023, 42(02): 156-161.
Chen Yanling, Zhuang Xiaodong, Xu Zhiwei, et al. Higenamine Combined with [6]-Gingerol Suppresses Doxorubicin-Triggered Oxidative Stress and Apoptosis in Cardiomyocytes via Upregulation of PI3K/Akt Pathway. [J]. Evidence-based complementary and alternative medicine: eCAM, 2013, 2013:970490.
Han Le, Ren Jing-Yi. Research progress of myocarditis and heart failure in tumor immunotherapy [J]. China Cardiovascular Journal, 2024, 29(02): 125-130.
Liao C Y, Wu L D, Liao M Y. Advances in the diagnosis and treatment of myocarditis associated with immune checkpoint inhibitors. China Contemporary Med, 2024, 31(17): 176-179.
CHARLES J, GIOVANNINI D, TERZI N, et al. Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation [J]. Exp Hematol Oncol, 2019, 8: 8.
DARNELL E P, MOORADIAN M J, BARUCH E N, et al. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls [J]. Curr Oncol Rep, 2020, 22(4): 39.
AGOSTINETTO E, EIGER D, LAMBERTINI M, et al. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials [J]. Eur J Cancer, 2021, 148: 76-91.
Wu L L, Ke R, Xu H Yun. Progress in diagnosis and treatment of cardiotoxicity associated with immune checkpoint inhibitors [J]. Journal of Modern Chinese and Western Medicine Combined, 2023, 32(21): 3044-3049.
Liu Q, Yang J M, GAO W C, et al. Protective effect of Shenqi Fuzheng injection on immune myocarditis injury induced by anti-PD-1 antibody [J]. Chinese Journal of Pharmacology, 2023, 39(10): 1980-1987.
SMALL H Y, MONTEZANO A C, RIOS F J, et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome [J]. Can J Cardiol, 2014, 30(5): 534-543.
HERRMANN J, YANG E H, ILIESCU C A, et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue [J]. Circulation, 2016, 133(13): 1272-1289.
ZHONG Xueke, Lin Jiayi, Zhang Qing. Advances in diagnosis and treatment of vascular complications associated with tumor therapy [J]. Tumor Prevention and Therapy, 2020, 33(02): 190-195. (in Chinese)
Wang T P, Rong Z, Tang H Y, et al. Treatment of Apatinib mesylate associated hypertension by nourishing Yin and clearing heat: a case report and experience [J]. Clinical Research of Traditional Chinese Medicine, 2017, 9(36): 15-16.
Guan Xianghua, Xu Jia, Dai Honghong. Effects of Yiqitongluo Decoction combined with felodipine sustained-release tablets on cardiac function and VEGF in elderly patients with essential hypertension and heart failure [J]. Medical Theory and Practice, 2020, 33(10): 1605-1607.
Ou Qiwei, Li Maoqing. Effects of traditional Chinese medicine for eliminating phlegm and clearing collaterals on blood pressure and vascular endothelial growth factor in patients with phlegm-stasis interjunction hypertension [J]. China Information Journal of Traditional Chinese Medicine, 2014, 21(06): 18-20.
Liu Wanmei. Effect of acupoint antihypertensive exercises on blood pressure control in patients with hypertension complicated by oral Apatinib [J]. World Latest Medical Information Digest, 2019, 19(46): 140+142.
LANCELLOTTI P, NKOMO V T, BADANO L P, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [J]. J Am Soc Echocardiogr, 2013, 26(9): 1013-1032.
DE HAAS E C, OOSTING S F, LEFRANDT J D, et al. The metabolic syndrome in cancer survivors [J]. Lancet Oncol, 2010, 11(2): 193-203.
Zhu W. Therapeutic effect of Xuefu Zhuyu Decoction on microvascular angina pectoris and its effect on vascular endothelial function [J]. Shaanxi Journal of Traditional Chinese Medicine, 2019, 40(01): 46-48.
Zang Juan, Li Panpan. Treating 35 cases of Qi deficiency and blood stasis syndrome of microvascular angina pectoris with Jianpi Yangxin formula based on the theory of deficient airflow [J]. Global Journal of Traditional Chinese Medicine, 2022, 15(10): 1950-1953.
JAMIESON S W, KAPELANSKI D P, SAKAKIBARA N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases [J]. Ann Thorac Surg, 2003, 76(5): 1457-1462; discussion 1462-1454.
SULASTOMO H, DINARTI L K, HARIAWAN H, et al. MicroRNA expression alteration in chronic thromboembolic pulmonary hypertension: A systematic review [J]. Pulm Circ, 2024, 14(3): e12443.
ZHAO Zhili, Zhao Yuanhong, Chen Maoyan, et al. Zhao Yuanhong's application of Huangqi Guizhi Wuwu Decoction in the treatment of venous embolism of lower extremities of lung cancer: a case report [J]. Shanghai Journal of Traditional Chinese Medicine, 2018, 52(12): 29-30.
Huang C J, Liu J B, Liao T H. Clinical effect of Taohong Siwu Decoction in the treatment of tumor patients with deep vein embolization [J]. Sichuan Traditional Chinese Medicine, 2015, 33(08): 98-101.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zhen Wang, Jianfeng Quan
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
